volume 12 issue 8 pages 553-563

The ERBB network: at last, cancer therapy meets systems biology

Publication typeJournal Article
Publication date2012-07-12
scimago Q1
wos Q1
SJR24.378
CiteScore103.8
Impact factor66.8
ISSN1474175X, 14741768
PubMed ID:  22785351
General Environmental Science
General Earth and Planetary Sciences
Abstract
This Timeline article focuses on the ERBB network of receptor tyrosine kinases, which exemplifies how a constant dialogue between basic and clinical cancer research can lead to the development of both novel drugs and strategies to overcome acquired resistance. Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.
Found 
Found 

Top-30

Journals

5
10
15
20
25
International Journal of Molecular Sciences
24 publications, 2.9%
Oncotarget
22 publications, 2.66%
Cancers
21 publications, 2.54%
PLoS ONE
19 publications, 2.3%
Frontiers in Oncology
18 publications, 2.18%
Frontiers in Pharmacology
11 publications, 1.33%
Cells
9 publications, 1.09%
Oncogene
9 publications, 1.09%
Scientific Reports
9 publications, 1.09%
Journal of Biological Chemistry
9 publications, 1.09%
Cell Death and Disease
8 publications, 0.97%
Molecular Oncology
8 publications, 0.97%
Clinical Cancer Research
8 publications, 0.97%
Molecular Cancer Therapeutics
8 publications, 0.97%
Nature Communications
7 publications, 0.85%
Proceedings of the National Academy of Sciences of the United States of America
7 publications, 0.85%
Bioorganic and Medicinal Chemistry Letters
6 publications, 0.73%
Revue des Maladies Respiratoires Actualites
6 publications, 0.73%
Cancer Science
6 publications, 0.73%
Pharmaceuticals
5 publications, 0.6%
Oncology Letters
5 publications, 0.6%
British Journal of Cancer
5 publications, 0.6%
Biomedicine and Pharmacotherapy
5 publications, 0.6%
Bioorganic Chemistry
5 publications, 0.6%
Cell Reports
5 publications, 0.6%
European Journal of Medicinal Chemistry
5 publications, 0.6%
Science Signaling
5 publications, 0.6%
Molecules
4 publications, 0.48%
Frontiers in Genetics
4 publications, 0.48%
5
10
15
20
25

Publishers

20
40
60
80
100
120
140
160
180
Elsevier
169 publications, 20.44%
Springer Nature
146 publications, 17.65%
MDPI
82 publications, 9.92%
Wiley
65 publications, 7.86%
Frontiers Media S.A.
48 publications, 5.8%
Taylor & Francis
34 publications, 4.11%
Public Library of Science (PLoS)
24 publications, 2.9%
American Chemical Society (ACS)
24 publications, 2.9%
Cold Spring Harbor Laboratory
24 publications, 2.9%
American Association for Cancer Research (AACR)
23 publications, 2.78%
Impact Journals
22 publications, 2.66%
Spandidos Publications
12 publications, 1.45%
Ovid Technologies (Wolters Kluwer Health)
12 publications, 1.45%
Royal Society of Chemistry (RSC)
10 publications, 1.21%
American Society for Biochemistry and Molecular Biology
9 publications, 1.09%
American Association for the Advancement of Science (AAAS)
8 publications, 0.97%
Proceedings of the National Academy of Sciences (PNAS)
7 publications, 0.85%
Bentham Science Publishers Ltd.
6 publications, 0.73%
SAGE
6 publications, 0.73%
Oxford University Press
6 publications, 0.73%
Hindawi Limited
5 publications, 0.6%
AME Publishing Company
5 publications, 0.6%
The Company of Biologists
4 publications, 0.48%
Institute of Electrical and Electronics Engineers (IEEE)
4 publications, 0.48%
Bioscientifica
3 publications, 0.36%
American Society for Microbiology
3 publications, 0.36%
eLife Sciences Publications
3 publications, 0.36%
American Society of Clinical Oncology (ASCO)
3 publications, 0.36%
PeerJ
2 publications, 0.24%
20
40
60
80
100
120
140
160
180
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
828
Share
Cite this
GOST |
Cite this
GOST Copy
Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology // Nature Reviews Cancer. 2012. Vol. 12. No. 8. pp. 553-563.
GOST all authors (up to 50) Copy
Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology // Nature Reviews Cancer. 2012. Vol. 12. No. 8. pp. 553-563.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/nrc3309
UR - https://doi.org/10.1038/nrc3309
TI - The ERBB network: at last, cancer therapy meets systems biology
T2 - Nature Reviews Cancer
AU - Yarden, Yosef
AU - Pines, Gur
PY - 2012
DA - 2012/07/12
PB - Springer Nature
SP - 553-563
IS - 8
VL - 12
PMID - 22785351
SN - 1474-175X
SN - 1474-1768
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2012_Yarden,
author = {Yosef Yarden and Gur Pines},
title = {The ERBB network: at last, cancer therapy meets systems biology},
journal = {Nature Reviews Cancer},
year = {2012},
volume = {12},
publisher = {Springer Nature},
month = {jul},
url = {https://doi.org/10.1038/nrc3309},
number = {8},
pages = {553--563},
doi = {10.1038/nrc3309}
}
MLA
Cite this
MLA Copy
Yarden, Yosef, and Gur Pines. “The ERBB network: at last, cancer therapy meets systems biology.” Nature Reviews Cancer, vol. 12, no. 8, Jul. 2012, pp. 553-563. https://doi.org/10.1038/nrc3309.